[1] Colonna M. Innate Lymphoid Cells: Diversity, Plasticity, and Unique Functions in Immunity. Immunity, 2018, 48(6): 1104-1117.
[2] Vivier E, Artis D, Colonna M, et al. Innate Lymphoid Cells: 10 Years On. Cell, 2018, 174(5): 1054-1066.
[3] Mao K, Baptista Ap, Tamoutounour S, et al. Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism. Nature, 2018, 554(7691): 255-259.
[4] Wang S, Xia P, Chen Y, et al. Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation. Cell, 2017, 171(1): 201-16 e18.
[5] Zhou W, Zhou L, Zhou J, et al. ZBTB46 defines and regulates ILC3s that protect the intestine. Nature, 2022, 609(7925): 159-165.
[6] Ferreira ACF, Szeto ACH, Heycock MWD, et al. RORalpha is a critical checkpoint for T cell and ILC2 commitment in the embryonic thymus. Nat Immunol, 2021, 22(2): 166-178.
[7] Fang D, Cui K, Cao Y, et al. Differential regulation of transcription factor T-bet induction during NK cell development and T helper-1 cell differentiation. Immunity, 2022, 55(4): 639-55 e7.
[8] Bal SM, Golebski K, Spits H. Plasticity of innate lymphoid cell subsets. Nat Rev Immunol, 2020, 20(9): 552-565.
[9] Cuff AO, Sillito F, Dertschnig S, et al. The Obese Liver Environment Mediates Conversion of NK Cells to a Less Cytotoxic ILC1-Like Phenotype. Front Immunol, 2019, 10: 2180.
[10] Saez A, Gomez-Bris R, Herrero-Fernandez B, et al. Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease. Int J Mol Sci, 2021, 22(14).
[11] Pelletier A, Stockmann C. The Metabolic Basis of ILC Plasticity. Front Immunol, 2022, 13: 858051.
[12] PANDA S K, COLONNA M. Innate Lymphoid Cells in Mucosal Immunity. Front Immunol, 2019, 10: 861.
[13] Ualiyeva S, Lemire E, Aviles EC, et al. Tuft cell-produced cysteinyl leukotrienes and IL-25 synergistically initiate lung type 2 inflammation. Sci Immunol, 2021, 6(66): eabj0474.
[14] Kobayashi T, Voisin B, Kim D Y, et al. Homeostatic Control of Sebaceous Glands by Innate Lymphoid Cells Regulates Commensal Bacteria Equilibrium. Cell, 2019, 176(5): 982-997 e16.
[15] Godinho-Silva C, Domingues RG, Rendas M, et al. Light-entrained and brain-tuned circadian circuits regulate ILC3s and gut homeostasis. Nature, 2019, 574(7777): 254-258.
[16] Seillet C, Luong K, Tellier J, et al. The neuropeptide VIP confers anticipatory mucosal immunity by regulating ILC3 activity. Nat Immunol, 2020, 21(2): 168-177.
[17] Talbot J, Hahn P, Kroehling L, et al. Feeding-dependent VIP neuron-ILC3 circuit regulates the intestinal barrier. Nature, 2020, 579(7800): 575-580.
[18] Serafini N, Jarade A, Surace L, et al. Trained ILC3 responses promote intestinal defense. Science, 2022, 375(6583): 859-863.
[19] Fumagalli V, Venzin V, Di Lucia P, et al. Group 1 ILCs regulate T cell-mediated liver immunopathology by controlling local IL-2 availability. Sci Immunol, 2022, 7(68): eabi6112.
[20] Klose C S N, Artis D. Innate lymphoid cells control signaling circuits to regulate tissue-specific immunity. Cell Res, 2020, 30(6): 475-491.
[21] Melo-Gonzalez F, Kammoun H, Evren E, et al. Antigen-presenting ILC3 regulate T cell-dependent IgA responses to colonic mucosal bacteria. J Exp Med, 2019, 216(4): 728-742.
[22] Wang YM, Shaw K, Zhang GY, et al. Interleukin-33 Exacerbates IgA Glomerulonephritis in Transgenic Mice Overexpressing B Cell Activating Factor. J Am Soc Nephrol, 2022, 33(5): 966984.
[23] Jackson-Jones LH, Duncan SM, Magalhaes MS, et al. Fat-associated lymphoid clusters control local IgM secretion during pleural infection and lung inflammation. Nat Commun, 2016, 7: 12651.
[24] Kato A. Group 2 Innate Lymphoid Cells in Airway Diseases. Chest, 2019, 156(1): 141-9.
[25] Friedrich C, Taggenbrock R, Doucet-Ladeveze R, et al. Effector differentiation downstream of lineage commitment in ILC1s is driven by Hobit across tissues. Nat Immunol, 2021, 22(10): 1256-1267.
[26] Heinrich B, Gertz EM, Schaffer AA, et al. The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut, 2022, 71(6): 1161-1175.
[27] Gao Y, Souza-Fonseca-Guimaraes F, Bald T, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol, 2017, 18(9): 1004-1015.
[28] Koh J, Kim HY, Lee Y, et al. IL23-Producing Human Lung Cancer Cells Promote Tumor Growth via Conversion of Innate Lymphoid Cell 1 (ILC1) into ILC3. Clin Cancer Res, 2019, 25(13): 4026-4037.
[29] Trabanelli S, Chevalier MF, Derre L, et al. The pro- and anti-tumor role of ILC2s. Semin Immunol, 2019, 41: 101276.
[30] Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer, 2019, 7(1): 267.
[31] Jeong WI, Park O, Suh YG, et al. Suppression of innate immunity (natural killer cell/interferon-gamma) in the advanced stages of liver fibrosis in mice. Hepatology, 2011, 53(4): 1342-1351.
[32] Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med, 2001, 7(1): 94-100.
[33] Curio S, Belz GT. The unique role of innate lymphoid cells in cancer and the hepatic microenvironment. Cell Mol Immunol, 2022, 19(9): 1012-1029. |
